Vaxart, Inc. (VXRT)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 4 | 1 | 0 | 7 | 29 | 237 | 243 | 82 |
| Operating profit | $m | 18 | 40 | ||||||
| Net profit | $m | -32 | -70 | -108 | -82 | -67 | 16 | 39 | -41 |
| EPS reported | $ | 0.07 | 0.15 | ||||||
| Operating cashflow per share | $ | 0.03 | 0.14 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | 0.03 | 0.14 | ||||||
| Free cash flow | $m | 8 | 33 | ||||||
| Net debt | $m | -64 | -64 | ||||||
| Book value equity | $m | 88 | 82 | ||||||
| Book value per share | $ | 0.38 | 0.34 | ||||||
| Number of shares | m | 230.35 | 242.17 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 5.00 | 3.06 | ||||||
| P/B LTM | x | 0.92 | 0.98 | ||||||
| P/S LTM | x | 0.34 | 0.33 | ||||||
| P/FCF LTM | x | 10.65 | 2.41 | ||||||
| EV/EBITDA LTM | x | 1.27 | 0.76 | ||||||
| EV/Sales LTM | x | 0.15 | 0.39 | ||||||
| Earnings Yield LTM | % | +20.00% | +32.68% | ||||||
| FCF Yield | % | +9.39% | +41.42% | ||||||
| Quality | |||||||||
| ROE | % | +18.60% | +53.04% | ||||||
| ROIC | % | +17.17% | +55.19% | ||||||
| Operating margin | % | +7.62% | +21.72% | ||||||
| Gross margin | % | +100.00% | +88.82% | ||||||
| FCF/Sales | % | +3.19% | +13.73% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +726.68% | +746.91% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.84 | 4.28 | ||||||
| Net Debt/EBITDA | x | -1.59 | -0.73 | ||||||
| EBIT/Net interest | x | 6.40 | 47.09 | ||||||
| Net debt/market cap | % | 0.00% | +5.66% | ||||||
| Net debt/Equity | x | -0.73 | -0.78 | ||||||
| Gross debt/equity | x | 0.10 | 0.09 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free